Abbott Labs ABT-874 for Treatment of Crohn’s Disease
November 11, 2004 by admin · Leave a Comment
On November 11, 2004 the results of an Abbott Labs Phase 2 Crohn’s disease clinical trial examining the safety and efficacy of ABT-874 were published in the New England Journal of Medicine. , ABT-874 is a monoclonal antibody designed to target interleukin-12 (IL-12). The authors concluded that treatment with ABT-874 may have caused clinical responses [...]
Humira (adalimumab) for rheumatoid arthritis
April 9, 2004 by admin · Leave a Comment
In December of 2002, Abbott Laboratories received FDA approval for Humira®, its human monoclonal antibody for the treatment of adults with moderate to severe rheumatoid arthritis. At that time, Biohorizon placed Humira in its High Impact Technology category and recommended preliminary assessment activites. In an April 2004 company news release, Abbott announced that worldwide sales [...]